Lactobacillus rhamnosus GG: The Most-Studied Probiotic Strain

← Back to articles

Lactobacillus rhamnosus GG (LGG, ATCC 53103) was isolated in 1983 from a healthy human gut and has become one of the most-studied probiotic strains in the world. Unlike most "gut health" blends, its evidence base is strain-specific and concentrated in a small number of well-defined indications.

Acute Diarrhoea in Children

The strongest evidence is in acute infectious diarrhoea in children. The Szajewska 2019 systematic review and meta-analysis in Alimentary Pharmacology & Therapeutics (PMID 31025399; DOI 10.1111/apt.15267) pooled 18 RCTs (n=4,208 children) and found LGG shortened diarrhoea duration by about 0.85 days (95% CI −1.15 to −0.56) and reduced length of hospital stay, with larger effects in European trials and smaller effects in non-European cohorts. ESPGHAN’s 2014 acute-gastroenteritis position paper (Szajewska 2014; PMID 24614141; DOI 10.1097/MPG.0000000000000320) lists LGG (alongside S. boulardii) as a probiotic with strong recommendation for use as an adjunct to rehydration. Effects are largest when given early in illness.

Antibiotic-Associated Diarrhoea

The Goldenberg 2015 Cochrane review of probiotics for pediatric antibiotic-associated diarrhoea (AAD) (PMID 26695080; DOI 10.1002/14651858.CD004827.pub4) pooled 23 RCTs (n=3,938) and found probiotics roughly halved AAD risk (RR 0.46, 95% CI 0.35–0.61, NNT~10). Among individual strains, LGG and S. boulardii at 5–40 billion CFU/day had the best supporting data. Typical adult and pediatric protocols use 10⁹–10¹⁰ CFU/day starting with the antibiotic and continuing 1–2 weeks after.

The Allergy and Eczema Story

Early trials suggested LGG in pregnancy and infancy might reduce eczema by age 2–4 in high-risk families. Replication has been mixed and current World Allergy Organization guidance concludes the overall evidence does not support a broad recommendation. Some benefit may exist in atopy-prone families, but the finding has not held up robustly.

What LGG Will Not Do

LGG has weak or absent evidence for IBS-D (other strains work better), Crohn’s maintenance, weight loss, mood, and generic "gut health" in asymptomatic adults. Matching strain to indication matters — generic "probiotic" marketing obscures the fact that most clinical benefits are strain-specific.

Dosing and Quality

Look for products labelled "Lactobacillus rhamnosus GG" with the ATCC 53103 designation — this is the specific researched strain. Typical dose 10⁹–10¹⁰ CFU/day. Refrigerate unless the product is specifically labelled shelf-stable. Culturelle and the Valio range deliver standardised LGG; cheaper generic "rhamnosus" products may use unrelated strains with little data. Avoid in severely immunocompromised patients and those with central venous catheters because of rare reports of bacteraemia.